

MAJ PETERSEN
Rare disease
Global Drug Discovery
Denmark



Science2Medicine iNNvest

Unlocking translatable opportunities in cardio-metabolism

High need for **innovation** to **impact the pipeline**

Novo Nordisk has experienced **tremendous recent growth** through our GLP-1 franchise



Historically, **cardio-metabolism** venture capital investment has been under-represented



Novo Nordisk is committed to **incentivise innovation** to seed for **future opportunities** in cardio-metabolism research

Science2Medicine

Unlocking the number of translatable opportunities in cardiometabolism

Science2Medicine **translationNN**

Big scientific challenges in co-creation partnerships. Up to € 300K

Science2Medicine **validationNN**

De-risking of scientific hypotheses through lean funding of killer experiments'. Up to € 50K

Science2Medicine **iNNvest**

Equity investments in promising biotechs. Up to \$7M investment size

Science2Medicine **creationNN**

Funding access to incubators and accelerators to promising start-ups



About the program


- Early stage (seed and series A)
- Up to 7 mUSD in first investment
- Follow lead investor
- Minority ownership positions (<20%)
- Observer seat and/or Scientific Advisory Board participation when appropriate

What are we looking for?

- Venture backed companies in **Diabetes, Obesity and CVD** with programs otherwise not accessible through classic BD collaboration/license structures
- Companies pursuing a relevant biology where co-investment would enable development for cardiometabolic indications



Pipeline impact
short- to mid-term



Deal flow
through venture

Partnering interests in cardio-metabolism

Diabetes



Transformational technologies and disease modifying therapies for diabetes that can prevent, stop/delay progression, induce remission or cure diabetes

Technologies and therapies that can prevent, **stop/delay development of complications**

Treatment options decreasing patient burden e.g. ultralow frequency of administration

Areas of high interest include but not limited to:

- Improvement of insulin sensitization
- Novel mechanism for glucose control with added benefit on weight and/or comorbidities
- Improvement of pancreatic islet health and beta-cell function
- Next generation of incretin and amylin-based therapies

Driving change | in diabetes

Obesity



Energy intake:

- Homeostatic control of feeding circuits in the CNS and hedonic feeding

Energy expenditure:

- Mitochondrial biology, substrate futile cycling, non-canonical thermogenesis pathways

Healthy weight management:

- Lean mass preservation
- Anti-inflammation and oxidative stress

Body weight control:

- Counter-regulatory mechanism on weight regain
- Vascular dynamics in metabolic active tissues
- Regulation of hormonal sensitivity

Driving change | in obesity

Cardiovascular Disease



ASCVD:


- Residual risk left after standard of care by targeting inflammation
- Dyslipidemia
- Endothelial & smooth muscle biology
- rHTN
- Refractory angina

Heart failure:

- HFpEF, HFrEF
- Cardiomyopathies
- Fibrosis

Driving change | in cardiovascular disease

Our organisational anchor



Novo Nordisk

Way

of Innovation Outreach